global
viru
network
gvn
establish
order
strengthen
research
respons
viral
caus
human
diseas
prepar
new
viral
pandem
threat
mann
gvn
center
excel
affili
countri
network
scientist
meet
annual
address
research
collabor
prioriti
learn
member
current
work
plan
futur
program
intern
confer
becom
critic
platform
exchang
idea
inform
go
http
wwwgvnorg
intern
gvn
meet
held
octob
hokkaido
japan
partnership
japanes
societi
virolog
jsv
nation
institut
infecti
diseas
japan
research
center
zoonosi
control
hokkaido
univers
brought
togeth
director
gvn
center
colleagu
two
day
scientif
present
discuss
emerg
reemerg
viral
threat
meet
report
highlight
accomplish
gvn
research
mani
prioriti
area
human
virolog
includ
current
zika
epidem
infect
human
papillomaviru
influenza
ebola
lassa
dengu
hiv
hepat
c
chikungunya
virus
develop
improv
diagnost
new
vaccin
sapporo
meet
first
gvn
event
held
jointli
local
nation
virolog
societi
jsv
member
opportun
attend
scientif
session
therebi
expand
opportun
collabor
dialogu
particularli
young
japanes
virologist
main
object
meet
present
discuss
current
find
medic
virolog
includ
advanc
research
hiv
vaccin
import
retrovirus
provid
framework
encourag
collabor
among
world
expert
address
gvn
annual
strategi
continu
develop
gvn
found
research
organ
independ
nation
govern
depth
expertis
need
respond
promptli
new
pandem
viral
outbreak
prepar
outbreak
gvn
intend
replac
organ
center
diseas
control
prevent
cdc
world
health
organ
complement
activ
independ
opinion
expertis
parallel
second
major
goal
gvn
advoc
strengthen
virolog
core
disciplin
infecti
diseas
help
develop
next
gener
virologist
dimaio
march
world
lead
virologist
gather
washington
dc
pledg
support
intern
coalit
virolog
institut
readi
act
time
outbreak
commit
advanc
knowledg
pathogen
virus
today
gvn
compris
center
excel
affili
countri
fig
center
led
worldclass
virologist
expertis
two
three
area
virolog
strong
public
record
commit
build
technic
scientif
capac
resourcepoor
countri
readi
support
gvn
infrastructur
albert
osterhau
phd
dvm
director
research
center
emerg
infect
zoonos
riz
univers
veterinari
medicin
hannov
germani
gvn
center
excel
present
robert
c
gallo
award
scientif
excel
leadership
pioneer
contribut
influenza
coronaviru
research
well
contribut
advanc
gvn
mission
osterhau
cite
decadeslong
career
includ
discoveri
new
human
anim
virus
help
combat
outbreak
mer
middl
east
respiratori
syndrom
sar
sever
acut
respiratori
syndrom
pandem
influenza
also
prais
leader
within
gvn
activ
particip
intern
confer
virolog
train
program
make
import
basic
scienc
contribut
medic
virolog
translat
contribut
broad
public
health
initi
award
name
robert
c
gallo
md
director
institut
human
virolog
univers
maryland
baltimor
cofound
scientif
director
gvn
dr
gallo
colleagu
discov
first
human
retrovirus
human
tcell
leukemia
viru
htlv
human
subsequ
demonstr
other
caus
roseola
gallo
gallo
codiscov
human
immunodefici
viru
hiv
caus
aid
togeth
colleagu
discov
one
first
cytokin
later
becam
critic
grow
continu
vitro
celllin
import
mani
immun
therapi
protocol
dr
gallo
colleagu
also
develop
first
blood
test
hiv
robert
gallo
review
recent
hiv
vaccin
trial
use
four
differ
method
thaiu
armi
trial
appear
given
modest
protect
earli
month
vaccin
other
fail
prevent
infect
one
case
associ
greater
infect
gallo
explain
last
sever
year
emphasi
induct
antibodi
hiv
envelop
compon
rather
primari
induct
cellular
immun
prevent
infect
approach
base
logic
tri
prevent
integr
establish
perman
infect
effort
mainli
evolv
around
two
program
first
detail
analysi
result
particularli
correl
protect
mainli
highlight
antibodi
interact
epitop
epitop
induc
interact
refer
ab
target
conserv
envelop
region
need
interact
function
correl
mainli
fc
effector
function
rather
neutral
antibodi
nab
second
major
approach
one
gear
toward
induc
broad
nab
reason
goal
one
met
prove
far
difficult
suppos
moreov
studi
nonhuman
primat
nhp
well
result
correl
protect
rare
nab
even
gener
gallo
also
describ
candid
immunogen
express
chimer
protein
shown
efficaci
heterolog
challeng
primat
correl
antibodi
fc
effector
activ
fout
et
al
vaccin
phase
trial
http
clinicaltrialsgovshow
like
antibodi
correl
protect
antibodi
persist
attempt
increas
persist
result
hyperactiv
tcell
form
target
hiv
infect
persist
boost
maintain
antibodi
lead
chang
antibodi
isotyp
reduc
efficaci
base
trial
recent
nhp
studi
gallo
conclud
two
critic
basic
scienc
problem
remain
solv
develop
success
antienvelop
hiv
vaccin
durabl
antibodi
correct
immun
balanc
yasushi
kawaguchi
univers
tokyo
describ
cell
factor
involv
uniqu
nuclearporeindepend
export
system
macromolecular
complex
nucleu
may
potenti
target
novel
antiherpet
drug
vesiclemedi
nucleocytoplasm
transport
uniqu
mechan
nuclear
export
macromolecular
complex
complex
nucleu
bud
inner
nuclear
membran
form
vesicl
perinuclear
space
primari
envelop
vesicl
fuse
outer
nuclear
membran
releas
complex
cytoplasm
deenvelop
type
transport
observ
herpesvirusinfect
mammalian
cell
export
viral
nucleocapsid
common
type
cell
indic
herpesvirus
may
expropri
mechan
oda
et
al
howev
cellular
mechan
vesiclemedi
nucleocytoplasm
transport
remain
larg
unknown
went
describ
recent
identifi
host
cell
protein
involv
uniqu
nuclear
export
system
protein
could
target
novel
antiherpet
drug
sinc
transport
system
essenti
life
cycl
herpesvirus
uniqu
biolog
hideki
hasegawa
gvn
center
director
nation
institut
infecti
diseas
tokyo
explain
secretori
iga
antibodi
mucos
surfac
play
import
role
protect
influenza
viru
infect
secretori
polymer
iga
antibodi
induc
intranas
inactiv
influenza
vaccin
higher
neutral
crossneutr
abil
homolog
heterolog
influenza
virus
compar
monomer
iga
antibodi
human
suzuki
et
al
method
produc
secretori
multimer
iga
antibodi
vitro
establish
recent
hasegawa
colleagu
examin
improv
neutral
effect
multimer
use
monoclon
iga
antibodi
method
vitro
product
multimer
iga
antibodi
establish
introduc
cdna
construct
h
l
j
chain
iga
secretori
compon
sc
cell
method
allow
product
larg
amount
recombin
monoclon
polymer
iga
antibodi
antibodycod
cdna
isol
clone
singl
plasma
cell
peripher
blood
mononuclear
cell
subject
previous
vaccin
intranas
inactiv
influenza
vaccin
monomer
multimer
iga
antibodi
specif
influenza
viru
prepar
function
analysisdsuch
elisa
neutral
testsdwa
perform
similar
secretori
iga
antibodi
human
nasal
wash
recombin
iga
show
polymer
antibodi
molecul
enhanc
neutral
activ
mass
spectrometri
analysi
found
antibodi
molecular
weight
kda
suggest
consist
mostli
tetram
form
tetramer
iga
antibodi
may
clinic
use
mucos
agent
prevent
treatment
influenza
erica
ollmann
saphir
gvn
center
codirector
scripp
research
institut
usa
report
recent
outbreak
ebola
viru
diseas
viral
diseas
urgent
need
novel
therapeut
monoclon
antibodi
offer
promis
solut
lack
current
avail
therapi
often
unclear
select
effect
antibodi
combin
optim
therapi
saphir
aman
integr
analysi
larg
array
antibodi
provid
ration
basi
select
optim
therapeut
lead
rapid
understand
mechan
underli
protect
efficaci
describ
result
fieldwid
analysi
antibodi
ebola
viru
particularli
potent
antibodi
marburg
viru
novel
panel
antibodi
lassa
viru
newli
form
intern
group
viral
hemorrhag
fever
immunotherapeut
consortium
aim
galvan
focu
effort
ebola
similar
virus
use
multidisciplinari
approach
saphir
et
al
sharon
lewin
gvn
center
director
doherti
institut
infect
immun
australia
report
hiv
cure
research
lederman
et
al
hiv
persist
predominantli
longliv
rest
cell
found
blood
greater
frequenc
tissu
hiv
also
persist
specif
tcell
subset
enrich
certain
tissu
site
includ
follicular
helper
cell
lymph
node
cell
gastrointestin
tract
longliv
infect
macrophag
specif
microglia
brain
kupffer
cell
liver
may
also
play
role
though
remain
controversi
art
hivspecif
cell
express
multipl
exhaust
marker
cell
often
unabl
recogn
kill
infect
cell
due
multipl
immun
escap
mutat
archiv
long
live
latent
infect
cell
furthermor
tissu
site
bcell
follicl
lymph
node
limit
penetr
hivspecif
tcell
lewin
describ
sever
approach
test
achiev
hiv
remiss
includ
reduc
latent
infect
cell
earli
art
latenc
revers
boost
immun
clearanc
reduc
immun
activ
homeostat
prolifer
elimin
tissu
reservoir
gene
therapi
make
cell
resist
hiv
recent
complet
clinic
trial
latencyrevers
agent
lra
hivinfect
patient
art
includ
histon
deacetylas
inhibitor
hdaci
highdos
disulfiram
delagr
everi
et
al
intervent
includ
activ
protein
kinas
c
pkc
bryostatin
ingenol
evalu
studi
hdaci
disulfiram
demonstr
hiv
transcript
activ
vivo
vari
effici
date
evid
intervent
alon
clear
latent
infect
cell
addit
recent
vitro
studi
shown
activ
transcript
hdaci
lra
may
lead
profound
chang
hiv
rna
splice
therefor
limit
potenc
concern
regard
hdaci
includ
shortand
longterm
toxic
chang
host
gene
express
advers
effect
immun
function
potent
specif
lra
necessari
develop
use
alon
combin
addit
intervent
promot
cell
death
may
need
target
inhibitor
antiapoptot
protein
iap
evalu
vitro
immunemedi
clearanc
bispecif
antibodi
broadli
neutral
antibodi
tcell
vaccin
clinic
develop
howev
even
number
latent
infect
cell
reduc
longterm
immun
control
requir
therapeut
vaccin
andor
immunomodul
immun
checkpoint
blocker
includ
antibodi
recent
licens
treatment
melanoma
potenti
attract
tool
enhanc
hivspecif
tcell
revers
latenc
clinic
trial
agent
start
hivinfect
individu
malign
shyamasundran
kottilil
institut
human
virolog
usa
describ
challeng
current
treatment
chronic
hepat
c
eightyf
percent
hcv
infect
becom
chronic
case
develop
cirrhosi
patient
progress
hepatocellular
carcinoma
andor
decompens
liver
lead
either
death
liver
transplant
contrast
chronic
hepat
b
hiv
infect
chronic
hcv
infect
cure
directact
antivir
daa
treatment
cure
defin
term
sustain
virolog
respons
svr
absenc
detect
level
hcv
rna
plasma
week
daa
treatment
jazwinski
muir
current
hcv
inhibitor
act
proteas
eg
asunaprivir
grazoprevir
protein
eg
daclatasvir
velpatasvir
polymeras
eg
sofosbuvir
beclabuvir
treatment
combin
two
inhibitor
sofosbuvir
velpatasvir
week
result
cure
treat
patient
still
clinic
challeng
remain
includ
treatment
patient
endstag
liver
renal
diseas
owe
metabol
andor
toxic
drug
challeng
includ
treatment
hivhcv
coinfect
inject
drug
user
pediatr
patient
maternalfet
transmiss
pregnanc
estaban
domingo
centro
de
molecular
severo
ochoa
spain
present
studi
popul
dynam
hcv
antivir
intervent
infect
human
hepatoma
cell
unexpectedli
serial
passag
hcv
cell
absenc
antivir
drug
result
increas
resist
inhibitor
target
viral
cellular
protein
associ
fit
gain
viru
daaresist
mutat
becom
widespread
human
popul
altern
drug
treatment
need
one
drug
favipiravir
furuta
et
al
broadspectrum
antivir
agent
activ
numer
rna
virus
includ
influenza
noroviru
rabi
rift
valley
fever
viru
act
lethal
mutagen
de
avila
et
al
efficaci
safeti
trial
favipiravir
treat
influenza
well
ebola
viru
diseas
alreadi
done
cell
cultur
efficaci
favipiravir
hcv
found
compar
efficaci
rna
virus
hcvinfect
cell
favipiravir
demonstr
featur
typic
lethal
mutagenesi
conclud
favipiravir
offer
altern
patient
chronic
infect
hcv
research
biomark
progress
human
papillomasviru
hpv
relat
cancer
highlight
session
franco
buonaguro
nation
cancer
institut
itali
buonaguro
describ
persist
infect
highrisk
hpv
often
associ
progress
mucos
cancer
anogenit
well
oropharyng
area
bodi
also
note
cervic
cancer
screen
program
avail
difficult
identifi
lesion
like
progress
invas
cancer
given
cervic
dysplasia
eventu
progress
biomark
clearli
need
tumor
progress
character
increas
express
viral
gene
degrad
increas
express
known
bind
inactiv
prb
integr
viral
dna
host
genom
consequ
disrupt
viral
gene
annunziata
et
al
molecular
marker
abl
identifi
viral
infect
associ
progress
cervic
neoplasia
strongli
need
screen
triag
particular
predict
biomark
need
detect
lesion
high
risk
recurr
progress
order
implement
appropri
treatment
avoid
overtreat
patient
high
probabl
regress
achiev
goal
express
profil
analysi
gene
genit
carcinoma
along
autolog
nontumor
tissu
perform
signific
differ
express
level
gene
involv
regul
apoptosi
cell
cycl
prolifer
dna
repair
pathway
identifi
moreov
oncogen
driver
mutat
critic
gene
recurr
chromosom
gainloss
oncogen
activ
hpv
integr
recogn
caus
deregul
cell
signal
pathway
cancer
progress
tornesello
et
al
recent
analysi
regulatori
region
human
gene
encod
cell
prolifer
protein
shown
high
frequenc
mutat
lesion
associ
less
oncogen
hpv
genotyp
even
hpvneg
lesion
valid
candid
biomark
current
way
larger
number
case
includ
differ
grade
hpvrelat
neoplast
lesion
invas
cervic
cancer
studi
contribut
develop
new
tool
identif
premalign
lesion
high
risk
progress
invas
cervic
carcinoma
jonathan
gershoni
gvn
center
director
tel
aviv
univers
israel
describ
analysi
vast
repertoir
antibodi
circul
polyclon
serum
igom
highlight
paratop
region
antibodi
mirror
correspond
region
antigen
eg
viru
protein
therefor
favor
indirect
approach
igom
profil
describ
peptid
interact
entiti
antibodi
spectrum
antibodi
specif
dynam
vari
age
physiolog
exposur
patholog
insult
igom
extraordinarili
rich
sourc
informationea
molecular
record
previou
encount
well
statu
report
current
immun
activ
weissottolenghi
gershoni
abil
profil
antibodi
specif
polyclon
serum
high
resolut
import
seriou
challeng
met
probe
record
qualifi
archiv
antibodi
present
serum
individu
vast
librari
peptid
gershoni
also
describ
deep
pan
methodolog
merg
flexibl
combinatori
phagedisplay
peptid
librari
power
nextgener
sequenc
enabl
highresolutionhighthroughput
interrog
igom
ryvkin
et
al
approach
produc
heatmap
character
interact
immun
system
antigen
method
use
character
differenti
sera
hivinfect
individu
versu
hcvinfect
individu
analyz
immun
respons
influenza
antigen
bird
jonathan
show
techniqu
could
use
monitor
character
effici
vaccin
suggest
igom
analysi
may
becom
use
tool
vaccin
develop
sinc
appear
chikungunya
viru
chikv
western
hemispher
gvn
special
focu
arbovirus
network
sponsor
joint
symposium
american
societi
tropic
medicin
hygien
global
spread
chikungunya
epidemiolog
evolut
pathogenesi
global
need
publish
special
report
describ
research
goal
public
health
prioriti
outbreak
mcsweegan
et
al
task
forc
intern
expert
also
form
provid
sourc
expert
inform
platform
collabor
marc
lecuit
gvn
center
institut
pasteur
pari
describ
chikv
geograph
spread
clinic
present
infect
develop
mous
model
allow
pathophysiolog
studi
evalu
novel
therapeut
murin
fibroblast
skelet
muscl
joint
capsul
dermi
found
primari
viral
target
type
ifnsens
nonhematopoiet
cell
critic
innat
immun
control
genomewid
sirna
screen
identifi
provir
antivir
host
factor
affect
viral
replic
allow
identif
potenti
drug
target
twentyon
small
molecul
inhibitor
affect
six
host
pathway
identifi
three
show
prophylact
effect
mous
model
calmodulin
inhibitor
pimozid
fatti
acid
synthesi
inhibitor
tofa
show
antivir
effect
mice
use
togeth
karla
et
al
experiment
data
show
chikv
infect
directli
target
placent
barrier
therefor
vertic
transmiss
virem
mother
neonat
like
occur
via
laborinduc
placent
breach
chikv
also
found
signific
caus
cn
diseas
larger
human
outbreak
viru
detect
affect
tissu
g
erardin
et
al
scott
weaver
chair
gvn
task
forc
zika
viru
zikv
review
sudden
emerg
zikv
rel
obscur
global
menac
serosurvey
shown
histor
incid
part
asia
africa
weaver
et
al
widespread
outbreak
micronesian
island
yap
later
expand
neighbor
island
south
pacif
coincid
outbreak
higher
incid
guillainbarr
syndrom
gb
note
explos
outbreak
brazil
began
involv
million
peopl
sinc
spread
countri
territori
western
hemispher
peridomest
mosquito
aed
aegypti
invas
aed
albopictu
mosquito
identifi
major
insect
vector
surprisingli
sexual
transmiss
zikv
also
confirm
travel
return
nonendem
region
disturb
aspect
recent
outbreak
high
incid
fetal
microcephali
birth
defect
directli
relat
infect
pregnant
women
weaver
also
discuss
import
knowledg
gap
infant
test
possibl
congenit
zika
infect
microcephali
among
neonat
tip
neurolog
iceberg
overal
risk
microcephali
birth
defect
seem
differ
part
latin
america
caribbean
compar
brazil
appear
new
outbreak
western
hemispher
caus
novel
viral
strain
instead
introduct
zikv
popul
via
rapid
global
travel
growth
tropic
citi
chang
vector
popul
seem
allow
viru
amplif
subsequ
epidem
spread
prospect
control
depend
mosquito
control
new
therapeut
develop
effect
vaccin
vaccin
prospect
appear
good
candid
develop
anim
model
avail
preclin
test
two
dnabas
vaccin
enter
phase
trial
inactiv
vaccin
near
phase
deploy
vaccin
howev
remain
depend
develop
accur
test
zikv
current
test
hamper
antigen
crossreact
zikv
close
relat
flavivirus
dengu
yellow
fever
st
loui
enceph
endem
geograph
area
richard
scheuermann
gvn
center
codirector
j
craig
venter
institut
usa
discuss
use
influenza
research
databas
ird
fludborg
viru
pathogen
resourc
vipr
viprbrcorg
identifi
diagnost
peptid
region
zika
viru
zikv
flavivirus
databas
identifi
diagnost
amino
acid
site
zikv
e
protein
respect
distinguish
flavivirus
sensitivityspecif
sun
et
al
similar
number
diagnost
site
also
identifi
flavivir
speci
slide
window
analysi
reveal
sever
contigu
peptid
region
contain
multipl
diagnost
site
specif
differ
flavivirus
region
use
develop
peptid
array
detect
antibodi
specif
virus
includ
zikv
peptid
array
could
signific
impact
diagnosi
epidemiolog
analysi
futur
diseas
outbreak
dian
griffin
gvn
center
john
hopkin
univers
usa
note
insectborn
virus
caus
enceph
becom
global
health
concern
due
recent
expans
new
region
fatal
rate
vari
mani
patient
recov
seriou
episod
viral
enceph
like
lifelong
physic
mental
disabl
viral
persist
immunemedi
clearanc
import
factor
sequela
griffin
describ
experi
sindbi
virusda
prototyp
alphavirusdus
varieti
mous
model
griffin
infect
neuron
adult
mice
result
nonfat
encephalomyel
recoveri
mediat
coordin
effort
antibodi
viral
surfac
protein
ifng
ifng
signal
lead
clinic
diseas
via
proinflammatori
cytokin
synergist
help
clear
viru
increas
bcellattract
chemokin
product
recruit
antibodyproduc
cell
central
nervou
system
cn
howev
noncytolyt
immun
phenomenon
lead
elimin
intracellular
viral
rna
longliv
neuron
continu
suppress
viru
prevent
reactiv
reemerg
cn
requir
immun
control
recoveri
evid
present
b
cell
infiltr
acut
phase
infect
remain
recoveri
continu
exert
protect
effect
local
longterm
resid
immun
cell
cn
like
facilit
continu
presenc
viral
protein
arthropod
make
largest
phylum
anim
kingdom
known
harbor
transmit
virus
agricultur
veterinari
medic
import
true
extent
virospher
arthropod
howev
larg
unknown
need
complet
explor
yongzhen
zhang
investig
nation
institut
communic
diseas
control
prevent
beij
china
present
work
newli
identifi
rna
virus
arthropod
collect
differ
region
china
among
recent
exampl
jingmen
tick
viru
jmtv
virus
belong
new
famili
chuvirida
qin
et
al
jtmv
four
genom
segment
sequenc
analysi
reveal
unexpect
connect
segment
nonseg
virus
chuvirus
exhibit
variou
genom
organ
includ
nonseg
biseg
circular
genom
virus
provid
evid
evolutionari
link
segment
nonseg
neg
strand
virus
overal
mani
novel
virus
repres
five
new
famili
discov
china
await
character
peter
pales
gvn
center
director
icahn
school
medicin
mount
sinai
usa
describ
ongo
effort
design
univers
influenza
vaccin
understand
immun
respons
construct
said
despit
avail
fdaapprov
vaccin
antivir
season
pandem
influenza
remain
seriou
threat
associ
substanti
morbid
mortal
annual
season
influenza
viru
vaccin
effect
e
albeit
underutil
countri
e
safe
univers
vaccin
provid
broad
longlast
immun
would
repres
major
breakthrough
today
licens
vaccin
focu
elicit
humor
immun
globular
head
hemagglutinin
ha
glycoprotein
antigen
subject
antigen
drift
requir
continu
surveil
circul
influenza
virus
sinc
pandem
research
effort
univers
vaccin
refocus
look
shift
immun
conserv
domain
ha
expect
cover
mani
circul
influenza
virus
pales
also
develop
vaccin
construct
express
chimer
hemagglutinin
cha
result
redirect
immun
respons
away
immunodomin
variant
head
domain
toward
much
conserv
stalk
region
also
express
highli
conserv
neuraminidas
na
tran
et
al
type
immunogen
demonstr
efficaci
follow
vaccin
mice
confer
heterosubtyp
protect
viru
challeng
mechan
approach
confer
antivir
activ
suggest
redirect
immun
stalk
region
preferenti
support
induct
antibodydepend
cellmedi
cytotox
adcc
data
present
show
broadli
neutral
ha
stalkspecif
antibodi
requir
fcgr
interact
protect
pales
propos
twocontact
model
optim
induct
adcc
influenza
virusspecif
mab
target
stalk
regiondand
globular
headdand
note
import
ha
bind
effector
cell
via
sialic
acid
receptor
requir
optim
adcc
induct
passiv
transfer
studi
mice
support
role
stalk
antibodi
protect
weight
loss
follow
viru
challeng
novel
technolog
support
govern
industri
support
gmpqualiti
batch
two
cha
immunogen
display
heterogen
globular
head
produc
evalu
clinic
studi
make
possibl
assess
role
addit
effector
mechan
protect
influenza
viru
infect
evalu
import
reduc
immunodomin
variabl
ha
head
domain
type
translat
studi
bring
us
step
closer
univers
influenza
vaccin
hiroshi
kida
hokkaido
univers
japan
report
establish
librari
avian
influenza
viru
strain
isol
duck
reassort
virus
gener
laboratori
combin
nine
na
sixteen
ha
subtyp
virusdbczchokudaiacjp
influenza
virus
known
subtyp
perpetu
among
migratori
duck
contribut
gene
gener
reassort
virus
pig
none
combin
rule
possibl
futur
pandem
strain
viru
librari
kept
sourc
vaccin
candid
assur
effect
prepared
futur
pandem
haredi
et
al
vaccin
construct
prepar
virus
librari
elicit
suffici
immun
respons
protect
chicken
mice
macaqu
challeng
isol
poultri
human
suggest
util
pandem
influenza
addit
note
current
season
vaccin
prepar
ether
deterg
disrupt
suffici
immunogen
especi
children
elderli
need
significantli
improv
furthermor
method
control
pandem
influenza
base
measur
use
control
season
influenza
hiroshi
note
inactiv
whole
virusbas
vaccin
candid
might
provid
solut
limit
current
vaccin
accomplish
goal
new
effect
influenza
vaccin
collabor
research
group
japan
collabor
studi
group
develop
influenza
vaccin
establish
april
five
japanes
manufactur
influenza
vaccin
particip
program
goal
studi
group
compar
immunogen
safeti
whole
viru
particl
vaccin
split
vaccin
use
result
preclin
clinic
trial
revis
standard
influenza
vaccin
human
use
determin
optimum
rout
inocul
evalu
proprietari
adjuv
massimo
palmarini
gvn
center
director
mrcunivers
glasgow
center
viru
research
scotland
report
studi
bluetongu
major
infecti
diseas
rumin
caus
doublestrand
rna
viru
known
bluetongu
viru
btv
studi
btv
sheep
offer
uniqu
perspect
understand
pathogenesi
arbovir
diseas
observ
made
natur
occur
diseas
effect
reproduc
conveni
experiment
set
use
anim
speci
caporal
et
al
clinic
outcom
btv
infect
sheep
extrem
variabl
similar
arboviru
infect
rapid
onset
antibodi
respons
correl
favor
clinic
outcom
btv
infect
natur
sheep
host
use
examin
previous
uncharacter
mechan
adopt
arboviru
manipul
host
immun
earli
stage
infect
btv
transport
rapidli
via
lymph
peripher
lymph
node
infect
disrupt
follicular
dendrit
cell
fdc
cell
stromal
origin
promot
format
mainten
germin
center
b
cell
differenti
memori
cell
plasma
cell
also
respons
support
antibodi
classswitch
affin
matur
work
show
btv
hinder
bcell
divis
germin
center
result
delay
product
highaffin
virusneutr
antibodi
importantli
humor
immun
respons
second
antigen
also
hamper
infect
sheep
thu
arboviru
evad
host
antivir
respons
induc
acut
immunosuppress
although
transient
immunosuppress
occur
critic
earli
stage
infect
delay
host
humor
immun
respons
like
affect
system
dissemin
viru
clinic
outcom
diseas
melzi
et
al
ab
osterhau
gvn
center
director
research
center
emergin
review
complex
relationship
among
human
anim
speci
promot
crossspeci
transmiss
emerg
eventu
evolut
plethora
human
pathogen
chang
affect
modern
human
popul
worldwid
dramat
impact
global
environ
taken
domest
agricultur
urban
industri
unpreced
level
creat
new
global
multifacet
humananim
interfac
associ
major
epidemiolog
transit
accompani
unexpect
surg
emerg
reemerg
human
infecti
diseas
origin
anim
reservoir
begin
last
centuri
infecti
diseas
major
caus
human
mortal
around
infect
caus
fifti
percent
death
western
world
follow
decad
percentag
decreas
less
percent
larg
due
implement
public
health
measur
instal
sewer
develop
clean
drink
water
system
also
develop
vaccin
antimicrobi
major
success
regard
erad
smallpox
rinderpest
wellorchestr
vaccin
campaign
human
cattl
respect
success
prompt
policymak
scientist
predict
infecti
diseas
humankind
domest
anim
would
eventu
brought
control
industri
world
paradox
follow
decad
confront
world
everincreas
number
emerg
reemerg
infecti
diseas
caus
true
human
anim
pandem
pathogen
spill
wildlif
reservoir
either
directli
via
intermedi
host
basi
outbreak
strike
exampl
human
emerg
aid
chimpanze
avian
flu
migratori
bird
sar
mer
ebola
viru
diseas
bat
reservoir
complex
mix
predispos
factor
global
world
link
major
chang
societ
environ
global
ecolog
collect
creat
opportun
virus
pathogen
infect
adapt
new
anim
human
host
pave
way
unpreced
spread
infect
dramat
consequ
public
anim
health
anim
welfar
food
suppli
economi
biodivers
import
realiz
complex
larg
interact
natur
predispos
factor
virtual
imposs
predict
next
pathogen
threat
come
strike
howev
better
understand
underli
process
may
eventu
lead
enhanc
predict
capac
improv
prepared
outbreak
human
anim
importantli
increas
emerg
viral
infect
larg
parallel
medic
veterinari
technolog
scientif
progress
invest
better
understand
humananim
interfac
offer
futur
head
start
struggl
infecti
diseas
human
ayato
takada
global
institut
collabor
research
educ
hokkaido
univers
sapporo
japan
describ
ebola
viru
glycoproteinspecif
monoclon
antibodi
mab
broadli
crossreact
known
ebola
viru
speci
mab
recogn
put
epitop
highli
conserv
intern
fusion
loop
ifl
neutral
infect
inhibit
membran
fusion
mab
may
therefor
potenti
therapeut
agent
anim
model
also
describ
novel
antibodydepend
enhanc
ade
mechan
fc
receptormedi
intracellular
signal
increas
uptak
ebola
viru
cell
vitro
furuyama
et
al
activ
fcreceptormedi
signal
pathway
essenti
ade
ebola
viru
infect
find
provid
new
insight
mechan
ade
develop
treatment
adeassoci
diseas
final
note
neutral
ade
antibodi
show
balanc
effect
depend
total
antibodi
concentr
rais
theoret
concern
use
convalesc
human
sera
plasma
low
antibodi
titer
therapeut
treatment
convalesc
sera
vitro
neutral
activ
suffici
protect
ebola
viru
infect
nonhuman
primat
mire
et
al
may
ade
antibodi
counterbalanc
neutral
capac
antibodi
laboratori
phenomena
warrant
evalu
luc
willem
gvn
investig
gembloux
agrobio
tech
belgium
describ
bovin
deltaretrovir
ribonucl
acid
induc
cell
transform
oncogenesi
among
strategi
develop
virus
escap
host
immun
respons
mechan
involv
viral
noncod
rna
recent
discov
virus
express
microrna
directli
target
cellular
transcript
other
produc
long
noncod
rna
act
microrna
spong
epigenet
modul
strategi
base
ribonucl
acid
control
cell
fate
without
elicit
immun
respons
due
absenc
viral
protein
viral
encod
mirna
first
identifi
dna
virus
gener
endonucleolyt
cleavag
long
viral
transcript
howev
retrovirus
initi
assum
encod
mirna
potenti
selfcleavag
rna
genom
gillet
et
al
date
four
retrovirusesbovin
leukemia
viru
blv
bovin
foami
viru
bfv
avian
leucosi
viru
alvj
simian
foami
viru
sfv
e
shown
express
viral
mirna
infect
cell
blv
natur
infect
bovin
speci
caus
benign
lymphocytosi
approxim
infect
lead
bcell
leukemialymphoma
remark
blv
persist
replic
vivo
absenc
signific
level
viral
mrna
transcript
contrast
blv
mirna
highli
express
infect
cell
repres
cellular
mirna
consequ
ribonucl
acid
like
less
immunogen
viral
protein
antigen
blv
mirna
could
alter
cell
fate
escap
immun
recognit
gillet
et
al
appear
chikv
western
hemispher
sudden
emerg
dissemin
zikv
driven
similar
cooper
respons
gvn
includ
format
second
task
forc
expert
exchang
inform
share
resourc
organ
webinar
busi
leader
inform
viru
prospect
therapi
vaccin
http
wwwbtsmeetingscomzika
provid
expert
inform
news
media
ensur
accur
report
acquir
grant
allergan
foundat
establish
bank
acut
convalesc
sera
confirm
zikv
patient
aid
develop
better
diagnost
among
accomplish
shyamasundran
kottilil
colleagu
institut
human
virolog
baltimor
began
project
gvn
fund
gilead
foundat
develop
train
model
physician
use
daa
treatment
hcv
patient
india
member
task
forc
publish
commentari
need
screen
prior
organ
transplant
agenda
futur
research
gallo
et
al
willem
et
al
gvn
investig
publish
new
research
west
nile
viru
rabi
viru
kobayashi
et
al
phongphaew
et
al
anindita
et
al
past
year
network
expand
number
cooper
research
center
ad
univers
miami
emori
univers
tulan
univers
school
medicin
usa
intern
vaccin
institut
south
korea
http
gvnorgco
center
expect
strengthen
cooper
research
vaccin
antivir
drug
emerg
virus
zikv
ebola
viru
among
project
gvn
staff
baltimor
expect
assist
pilot
studi
hepat
b
arunach
pradesh
india
fund
john
martin
foundat
project
screen
peopl
provid
vaccin
infect
develop
longitudin
cohort
treat
patient
chronic
hepat
b
infect
member
gvn
task
forc
expect
publish
addit
commentari
review
similarli
gvn
task
forc
report
zikv
emerg
research
prioriti
prepar
gvn
staff
also
continu
seek
addit
patient
serum
sampl
zikv
serum
bank
base
univers
texa
medic
branch
galveston
texa
addit
project
sequenc
conduct
phylogenet
analys
collect
zika
viru
isol
begun
cooper
world
refer
center
emerg
virus
arbovirus
wrceva
fund
nation
institut
allergi
infecti
diseas
usa
gvn
host
fourth
annual
short
cours
medic
virolog
young
investig
short
cours
attract
intern
class
postdoctor
student
fellow
five
day
meet
lectur
expert
medic
virolog
research
clinic
practic
inform
cours
registr
avail
onlin
http
wwwgvnorg
intern
gvn
meet
melbourn
australia
septemb
cohost
gvn
center
excel
institut
pasteur
pari
peter
doherti
institut
infect
immun
melbourn
